Breaking News, Collaborations & Alliances

Andelyn Biosciences Partners with Grace Science to Advance GS-100

Will tech transfer Phase I/II/III manufacturing of the suspension process adeno-associated virus (aav) gene therapy for NGLY1 deficiency.

Author Image

By: Charlie Sternberg

Associate Editor

Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Grace Science LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.   NGLY1 Deficiency is a serious, life-threatening disease with no approved therapy. Patients with this disease suffer from a lifetime of debilitating symptoms. The partnership will se...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters